Search | Médecins Sans Frontières Access Campaign

The combination of sofosbuvir/ledipasvir (SOF/LDV) represents a more powerful and effective all-oral treatment for hepatitis C (HCV), particularly for people with genotype 1 HCV

Tags Hepatitis C hepatitis C sofosbuvirledipasvirdirect-acting antiviralsFDCs intellectual property & trade

Statement |

14 September 2014

MSF Access Campaign response to Gilead’s deal with generic companies for sofosbuvir and ledipasvir

Tags Hepatitis C sofosbuvirledipasvirdirect-acting antivirals intellectual property & trade Gilead India

Statement |

27 August 2014

Hepatitis C drug daclatasvir approved by European Commission

Tags Hepatitis C hepatitis C sofosbuvirdaclatasvirdirect-acting antivirals intellectual property & trade European CommissionBristol-Myers Squibb

Statement |

24 February 2014

MSF response to European Parliament proposals of EU enforcement of European trademarks on goods in transit

Tags Intellectual property and trade generic medicinesTRIPSuniversal access European Commission European Union

Statement |

21 February 2014

MSF response to the licensing deal announced between Merck Sharp & Dohme and Cipla for the HIV medicine raltegravir

Tags HIV/AIDS raltegravirantiretroviral medicines compulsory licencegeneric medicinesintellectual property & trade CiplaMerck

Statement |

07 February 2014

MSF responds to reports on Gilead pricing for hepatitis C drug sofosbuvir in developing countries

Tags Hepatitis C hepatitis C sofosbuvir diagnostic testsgeneric medicinesintellectual property & tradevoluntary licence Gilead

Statement |

28 January 2014

MSF intervention at WIPO Standing Committee on the Law of Patents

Tags Intellectual property and trade access to medicinesgeneric medicines South Africa

Statement |

23 January 2014

MSF intervention on access to medicines at WHO 134th Executive Board meeting

Tags Intellectual property and tradeResearch and development access to medicinesgeneric medicinesTRIPS World Health Organization South Africa

Statement |

20 January 2014

MSF urges South Africa to stand strong in defiance of aggressive pharma moves to delay change

Tags Intellectual property and trade evergreeninggeneric medicinesTRIPS Fix the Patent Laws Campaign South AfricaIndia

Date

Primary topics

Types of content

Products

Diseases

General Terms

Geography

Campaigns

Institutions & Events

Report series

Miscellaneous

Tribute to Dr Amit Sengupta

MSF Statement on the WHO Roadmap for access 2019 -2023: Comprehensive support for access to medicines and vaccines

MSF hearing statement for the USTR 2017 Special 301 Review

MSF comments to the Department of Defense intent to grant exclusive license of patents on a Zika vaccine candidate

MSF intervention at the 25th WIPO Standing Committee on Patents

Médecins Sans Frontières UNAIDS PCB Intellectual Property intervention

MSF general statement at the 56th Series of WIPO Assembly

Civil society urges Member States to support the Dutch EU Presidency’s vision on access to affordable medicines

MSF and over 50 groups urge US Congress to reject the TPP

India: MSF submission to IP Think Tank committee on draft IP policy

136th WHO EB - MSF intervention on GSPA on public health, innovation and intellectual property

MSF responds to USFDA approval of first combination hepatitis C treatment

MSF Access Campaign response to Gilead’s deal with generic companies for sofosbuvir and ledipasvir

Hepatitis C drug daclatasvir approved by European Commission

MSF response to European Parliament proposals of EU enforcement of European trademarks on goods in transit

MSF response to the licensing deal announced between Merck Sharp & Dohme and Cipla for the HIV medicine raltegravir

MSF responds to reports on Gilead pricing for hepatitis C drug sofosbuvir in developing countries

MSF intervention at WIPO Standing Committee on the Law of Patents

MSF intervention on access to medicines at WHO 134th Executive Board meeting

MSF urges South Africa to stand strong in defiance of aggressive pharma moves to delay change